Editorial board member Peter J Barnes (Imperial College, London, UK) discusses the rationale and findings of the late-breaking presentation he was involved with entitled: Risk of a severe exacerbation following higher reliever use: post-hoc analysis of SYGMA-1 in mild asthma.
1. What are the limitations of current reliever medications for mild asthma? (0:12)
2. What were the rationale for and objectives of the SYGMA-1 study? (0:47)
3. What were the findings of the recent post-hoc analysis of SYGMA-1? (2:01)
4. What are the next steps in the clinical development of the budesonide/formoterol Turbuhaler? (3:02)
5. What developments in asthma management have excited you most in the last year? (3:57)
Speaker disclosure: Peter J Barnes has received research funding from AstraZeneca and Boehringer Ingelheim and has been on advisory boards and given lectures for AstraZeneca, Boehringer Ingelheim, Chiesi, Novartis and Teva Pharmaceutical Industries Ltd.
Filmed at the European Respiratory Society (ERS) International Congress 2018, Paris, France, September 2018.
Share this Video
Related Videos In Asthma
Andrew Menzies-Gow, ERS 2021: Personalised Treatment for Severe Asthma
It was a pleasure to meet with Professor Andrew Menzies-Gow (Royal Brompton Hospital and Imperial College London, London, UK) to talk around personalised treatment and emerging hot topics in severe asthma. Questions How can we further personalise treatment for people with severe asthma? (0:11) What are the hot topics and latest research you are looking […]
Andrew Menzies-Gow, ERS 2021: Benralizumab Following Oral Corticosteroid Reduction in Severe Asthma
TouchRESPIRATORY got the opportunity to catch up with Professor Andrew Menzies-Gow (Royal Brompton Hospital and Imperial College London, London, UK) to discuss oral corticosteroid (OCS) dependency in severe asthma and the use of benralizumab following OCS reduction. The abstract ‘Durable clinical benefit of benralizumab following oral corticosteroid reduction: The PONENTE study.’ (ID:1460) was presented at […]
Sarah Diver, ATS 2021: The CASCADE Study
TouchRESPIRATORY got the opportunity to catch up with Dr Sarah Diver (University of Leicester, Leicester, UK) around the CASCADE study, investigating the use of tezepelumab in patients with moderate-to-severe uncontrolled asthma. ‘Effect of tezepelumab on airway inflammatory cells, remodeling and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma: a randomized, double-blind, placebo-controlled trial’ was presented at […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!